Review of the safety, efficacy and patient acceptability of the combined dienogest/ estradiol valerate contraceptive pill

International Journal of Women's Health

Volumn 2, Issue 1, 2010, Pages 279-290

  Guida, Maurizio ^a   Bifulco, Giuseppe ^a   di Spiezio Sardo, Attilio ^a   Scala, Mariamaddalena ^a   Sosa, Loredana Maria ^a   Nappi, Fernandez Carmine ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Combined oral contraceptive; Contraceptive safety; Dienogest; Estradiol valerate; Four phasic regimen

Indexed keywords

DIENOGEST; DIENOGEST PLUS ESTRADIOL VALERATE; ERYTHROMYCIN; ESTRADIOL VALERATE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; KETOCONAZOLE; PLACEBO; QLAIRA; RIFAMPICIN; UNCLASSIFIED DRUG;

ACNE; ALOPECIA; AMENORRHEA; AREA UNDER THE CURVE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSMENORRHEA; HORMONAL CONTRACEPTION; HUMAN; MASTALGIA; MENSTRUAL CYCLE; METRORRHAGIA; MIGRAINE; OVULATION; PATIENT SATISFACTION; PHARMACODYNAMICS; PROTEIN BLOOD LEVEL; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; VAGINITIS; WEIGHT GAIN;

EID: 77956975279     PISSN: None     EISSN: 11791411     Source Type: Book Series    
DOI: 10.2147/IJWH.S6954     Document Type: Review

References (68)

1. Mosher WD, Martinez GM, Chandra A, Abma JC, Willson SJ. Use of contraception and use of family planning services in the United States: 1982-2002. Adv Data. 2004;350:1-36.
2. Meade T W. Risks and mechanisms of cardiovascular events in users of oral contraceptives. Am J Obstet Gynecol. 1988;158:1646-1652.
3. /. Accessed November 17, 2009.
4. Loose DS, Stancel GM. Estrogens and progestins. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman and Gilman's the Pharmacological Basis of Therapeutics. 11th ed. New York: McGraw-Hill; 2005. p. 1541-1571.
5. Graziottin A. Che cosa vogliono le donne nella contraccezione. Che cosa può offrire Klaira. Contraccezione Fertilità Sessualità. Numero speciale. 2009;36:23-28.
6. ®. Contraccezione Fertilità Sessualità. Numero speciale. 2009;36:5-10.
7. Ahrendt HJ, Makalová D, Parke S, Mellinger U, Mansour D. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/ dienogest and ethinyl estradiol/levonorgestrel. Contraception. 2009;80(5):436-444.
8. Zeun S, Lu M, Uddin A, Zeiler B, Morrison D, Blode H. Pharmacoki-netics of an oral contraceptive containing oestradiol valerate and dieno-gest. Eur J Contracept Reprod Health Care. 2009;14(3):221-232.
9. Oettel M, Graser T, Hoffman H. Why dienogest as a progestogenic component of postmenopausal nonandrogenic hormone replacement therapy. Drugs Today (Barc). 2001;37:3-15.
10. Mueck AO, Seeger H. Pharmacology of dienogest. Gyneacology Forum. 2009;14:9-12.
11. Zimmerman H, Thebault JJ, Duvauchelle T, et al. Pharmacokinetics of estradiol valerate 2 mg + dienogest 2 mg after single and repeated oral administration in healty postmenopausal women. Clin Drug Investig. 2000;20:123-134.
12. Mashchak CA, Lobo RA, Dozono-Takano R, et al. Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynecol. 1982;144(5):511-518.
13. Wiegratz I, Lee JH, Kutschera E, Winkler UH, Kuhl H. Effect of four oral contraceptives on hemostatic parameters. Contraception. 2004;70(2):97-106.
14. Lindberg UB, Crona N, Stigendal L, Teger-Nilsson AC, Silfverstolpe G. A comparison between effects of estradiol valerate and low dose ethinynil estradiol on haemostasis parameters. Thromb Haemost. 1989;61(1):65-69.
15. Helgason S. Estrogen replacement therapy after the menopause. Estrogenicity and metabolic effects. Acta Obstet Gynecol Scand Suppl. 1982;107:1-29.
16. Oral Contraceptive and Hemostasis Study Group. The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study. Contraception. 2003;67(3):173-185.
17. Kuhl H. Effects of progestogens on haemostasis. Maturitas. 1996;24(1-2):1-19.
18. Winkler UH. Effects on hemostatic variables of desogestrel-and gestodene-containing oral contraceptives in comparison with levonorgestrel-containing oral contraceptives: a review. Am J Obstet Gynecol. 1998;179(3 Pt 2):S51-S61.
19. Norris LA, Bonnar J. The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives. Br J Obstet Gynaecol. 1996;103(3):261-267.
20. Mueck AO, Seeger H, Lüdtke R, Gräser T, Wallwiener D. Effect on biochemical vasoactive markers during postmenopausal hormone replacement therapy: estradiol versus estradiol/dienogest. Maturitas. 2001;38(3):305-313.
21. Blode H, Schott B, Rohde M, Kunz M, Zeun S, editors. Effects of CY3A4 induction and inhibition on the pharmacokinetics of estradiol valerate/dienogest. Proceedings of the 11th world congress on controversies in obstetrics gynecology and infertility; 2008 Nov. p. 27-30; Paris, France.
22. Endrikat J, Parke S, Trummer D, Schmidt W, Duijkers I, Klipping C. Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies. Contraception. 2008;78(3):218-225.
23. ®. Drugs Today (Barc). 1999;35 Suppl C:53-68.
24. Hoogland HJ, Skouby SO. Ultrasound evaluation of ovarian activity under oral contraceptives. Contraception. 1993;47(6):583-590.
25. ®: a natural change of direction. J Fam Plann Reprod Health Care. 2009;35(3):139-142.
26. A randomized, double-blind study of two combined oral contraceptives containing the same progestogen, but different estrogens. World Health Organization Task Force on Oral Contraception. Contraception. 1980;21(5):445-459.
27. Schubert W, Cullberg G. Ovulation inhibition with 17 beta-estradiol cyclo-octyl acetate and desogestrel. Acta Obstet Gynecol Scand. 1987;66(6):543-547.
28. Serup J, Bostofte E, Larsen S, Westergaard J, Lebech PE. Natural oestrogens for oral contraception. Lancet. 1979;2(8140): 471-472.
29. Nahum GG, Parke S, Wildt L, et al. Effcacy and tolerability of a new oral contraceptive containing estradiol and dienogest [abstract]. Obstet Gynecol. 2008;111 Suppl 4:S15. Poster presentation from the American College of Obstetricians and Gynecologists 56th Annual Clinical Meeting; 2008 May 3-7; New Orleans, LA.
30. Wiegratz I, Kutschera E, Lee JH, et al. Effect of four different oral contraceptives on various sex hormones and serum-binding globulins. Contraception. 2003;67(1):25-32.
31. Refn H, Kjaer A, Lebech AM, Borggaard B, Schierup L. Clinical and hormonal effects of two contraceptives: correlation to serum concentrations of levonorgestrel and gestodene. Contraception. 1990;41(3): 259-269.
32. Kuhl H, Jung-Hoffmann C, Weber J, Boehm BO. The effect of a biphasic desogestrel-containing oral contraceptive on carbohydrate metabolism and various hormonal parameters. Contraception. 1993;47(1): 55-68.
33. Gaspard UJ, Romus MA, Gillain D, Duvivier J, Demey-Ponsart E, Franchimont P. Plasma hormone levels in women receiving new oral contraceptives containing ethinyl estradiol plus levonorgestrel or desogestrel. Contraception. 1983;27(6):577-590.
34. Aden U, Jung-Hoffmann C, Kuhl H. A randomized cross-over study on various hormonal parameters of two triphasic oral contraceptives. Contraception. 1998;58(2):75-81.
35. Kuhl H, Gahn G, Romberg G, März W, Taubert HD. A randomized cross-over comparison of two low-dose oral contraceptives upon hormonal and metabolic parameters: I. Effects upon sexual hormone levels. Contraception. 1985;31(6): 583-593.
36. Jung-Hoffmann C, Heidt F, Kuhl H. Effect of two oral contraceptives containing 30 micrograms ethinylestradiol and 75 micrograms gestodene or 150 micrograms desogestrel upon various hormonal parameters. Contraception. 1988;38(6): 593-603.
37. Luciano AA, Sherman BM, Chapler FK, Hauser KS, Wallace RB. Hyperprolactinemia and contraception: a prospective study. Obstet Gynecol. 1985;65(4):506-510.
38. Parke S, Nahum GG, Mellinger U, Junge W. Metabolic effects of a new 4-phasic combined oral contraceptive containing estradiol valerate and dienogest. Poster presented at the American College of Obstericians and Gynecologists 56th Annual Meeting; 2008 May 3-7; New Orleans, LA. Obstet and Gynecol. 2008;111 Suppl 4:125.
39. Helmerhorst FM, Rosendaal FR, Vandenbroucke J P. Venous thromboembolism and the pill. The WHO technical report on cardiovascular disease and steroid hormone contraception: state-of-the-art. World Health Organization. Hum Reprod. 1998;13(11): 2981-2983.
40. Herings RM, Urquhart J, Leufkens HG. Venous thromboembolism among new users of different oral contraceptives. Lancet. 1999;354(9173):127-128.
41. Bloemenkamp K W, Rosendaal FR, Helmerhorst FM, Vandenbroucke J P. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med. 2000;160(1):49-52.
42. Lidegaard O, Edström B, Kreiner S. Oral contraceptives and venous thromboembolism: a fve-year national case-control study. Contraception. 2002;65(3):187-196.
43. Wiegratz I, Stahlberg S, Manthey T, et al. Effects of conventional or extended-cycle regimen of an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on various hemostasis parameters. Contraception. 2008;78(5):384-391.
44. Meade T W. Oral contraceptives, clotting factors, and thrombosis. Am J Obstet Gynecol. 1982;142(6 Pt 2):758-761.
45. Gerstman BB, Piper JM, Tomita DK, Ferguson WJ, Stadel B V, Lundin FE. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol. 1991;133(1):32-37.
46. Lidegaard O. Oral contraception and risk of a cerebral thromboembolic attack: results of a case-control study. BMJ. 1993;306(6883):956-963.
47. Sabra A, Bonnar J. Hemostatic system changes induced by 50 micrograms and 30 micrograms estrogen/progestogen oral contraceptives. Modifcation of estogen effects by levonorgestrel. J Reprod Med. 1983;28 Suppl 1:S85-S91.
48. Parke S, Junge W, Mellinger U, Duijkers I, Klipping C. Comparative effects of four-phasic regimen of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrel on haemostatic parameters. Proceeding of the 24th Annual Meeting of the ESHRE; 2008 July 7-9; Barcelona, Spain.
49. Spona J, Feichtinger W, Kindermann C, et al. Double-blind, randomized, placebo controlled study on the effects of the monophasic oral contraceptive containing 30 micrograms ethinyl estradiol and 2.00 mg dienogest on the hemostatic system. Contraception. 1997;56(2):67-75.
50. Winkler UH, Schindler AE, Endrikat J, Düsterberg B. A comparative study of the effects of the hemostatic system of two monopha-sic gestodene oral contraceptives containing 20 micrograms and 30 micrograms ethinylestradiol. Contraception. 1996;53(2):75-84.
51. Winkler UH, Daume E, Sudik R, et al. A comparative study of the hemostatic effects of two monophasic oral contraceptives containing 30 μg ethinylestradiol and either 2 mg chlormadinone acetate or 150 μg desogestrel. Eur J Contracept Reprod Health Care. 1999;4(3):145-154.
52. Quehenberger P, Loner U, Kapiotis S, et al. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives. Thromb Haemost. 1996;76(5):729-734.
53. Winkler UH, Hölscher T, Schulte H, Zierleyn J P, Collet W, Schindler AE. Ethinylestradiol 20 versus 30 micrograms combined with 150 micrograms desogestrel: a large comparative study of the effects of two low-dose oral contraceptives on the hemostatic system. Gynecol Endocrinol. 1996;10(4):265-271.
54. Winkler UH, Oberhoff C, Bier U, Schindler AE, Gillain D. Hemostatic effects of two oral contraceptives containing low doses of ethinyl estradiol and either gestodene or norgestimate: an open, randomized, parallel-group study. Int J Fertil Menopausal Stud. 1995;40(5):260-268.
55. Cachrimanidou AC, Hellberg D, Nilsson S, von Schoulz B, Crona N, Siegbahn A. Hemostasis profle and lipid metabolism with long-interval use of a desogestrel-containing oral contraceptive. Contraception. 1994;50(2):153-165.
56. Tans G, Curvers J, Middeldorp S, et al. A randomized cross-over study on the effects of levonorgestrel-and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost. 2000;84(1):15-21.
57. Malm J, Laurell M, Dahlbäck B. Changes in the plasma levels of vitamin K-dependent proteins C and S and of C4b-binding protein during pregnancy and oral contraception. Br J Haematol. 1988;68(4):437-443.
58. Petersen KR, Sidelmann J, Skouby SO, Jespersen J. Effects of monophasic low-dose oral contraceptives on fbrin formation and resolution in young women. Am J Obstet Gynecol. 1993;168(1 Pt 1):32-38.
59. Archer DF, Mammen EF, Grubb GS. The effects of a low-dose monophasic preparation of levonorgestrel and ethinyl estradiol on coagulation and other hemostatic factors. Am J Obstet Gynecol. 1999;181(5 Pt 2):63-66.
60. Melissari E, Kakkar V V. The effects of oestrogen administration on the plasma free protein S and C4b-binding protein. Thromb Res. 1988;49(5):489-495.
61. Granata A, Sobbrio GA, D'Arrigo F, et al. Changes in the plasma levels of proteins C and S in young women on low-dose oestrogen oral contraceptives. Clin Exp Obstet Gynecol. 1991;18(1):9-12.
62. Nelson A, Sampson-Landers C, Parke S, et al. Effcacy of estradiol valerate/dienogest oral contraceptive: results of 3 large studies in North America and Europe [abstract plus poster]. Proceeding of the American College of Obstetricians and Gynecologists 57th Annual Clinical Meeting; 2009 May 2-6; Chicago, IL.
63. Fruzzetti F, Perini D, Lazzarini V. Etinil Estradiolo diventa Estradiolo. Proflo clinico di Klaira. Contraccezione Fertilità Sessualità. Numero speciale. 2009;36:11-18.
64. Oettel M, Carol W, Elger W, et al. A 19-norprogestin without 17alfa-ethinil group II: dienogest from a pharmacodynamic point of view. Drugs Today (Barc). 1995;31:517-536.
65. Lu M, Uddin A, Foegh M, Zeun S. Pharmacocynetics and pharmacodynamic of a new four-phasic estradiol valerate and dienogest oral contraceptive. Obstet Gynecol. 2007;109:61S.
66. Golbs S, Domhardt R, Presl J, et al. Clinical fndings with the oral contraceptive combination ethinylestradiol/dienogest in the Czech Republic. Methods Find Exp Clin Pharmacol. 2002;24:689-696.
67. Golbs S, Domhardt R, Radowicky S, et al. Clinical fndings with the oral contraceptive combination ethinylestradiol/dienogest in Poland. Methods Find Exp Clin Pharmacol. 2002;24:585-592.
68. Zimmermann T, Dietrich H, Wisser KH, Hoffmann H. The effcacy and tolerability of Valette: a post marketing surveillance study. Eur J Contracept Reprod Health Care. 1994;4:155-164.